‘Vitamin R’ and Its Younger Siblings
February 15, 2010ByRoger M. Macklis, MD
No branch of oncology has been more attuned to the vision of new genetically engineered targeted therapies than the field of hematopoietic malignancies. Ujjani and Cheson have produced a masterful summary of one extremely important component of the targeted therapy revolution-the realm of monoclonal antibodies directed against malignant lymphoma surface antigens. The review presents a wonderful update and a glimpse of future potentially curative macromolecular cocktails. It is an attractive vision.